The Affordable Premiums for Seniors Act of 2026 extends a Medicare Part D premium stabilization program through 2029 and makes it permanent starting in 2030, provided that ending the program would not cause prescription drug premiums to rise. This legislation directly affects seniors enrolled in Medicare prescription drug plans by aiming to keep their costs stable over time. The bill requires the Secretary of Health and Human Services to issue updated operational guidelines for the program within 30 days of enactment.
Ensuring Access to Lower-Cost Medicines for Seniors Act This bill requires prescription drug plans under the Medicare prescription drug benefit to include generic drugs and biosimilars on their formularies. Specifically, the bill requires plans that use formularies to include generic drugs and biosimilars on the formularies and without any requirements (e.g., prior authorization requirements) that are more restrictive as compared to those for brand-name drugs and biologics. Plans that use cost-sharing tiers must also have specific tiers for generic drugs and biosimilars, in accordance with certain limitations.
This bill requires Medicare Part D prescription drug plans to include certain lower-cost generic drugs and biosimilar biological products in preferred positions on their formularies starting in 2027. It mandates that these lower-cost alternatives be placed on more favorable tiers with reduced out-of-pocket costs compared to their brand-name counterparts. Additionally, the legislation prohibits plans from imposing stricter access restrictions, such as prior authorization or step therapy, on these lower-cost options than those applied to the original brand-name drugs. The measure directly affects Medicare beneficiaries enrolled in Part D plans and the insurance sponsors who manage those formularies.
HR 1244, the "Reducing Drug Prices for Seniors Act," requires Medicare Part D plans to calculate coinsurance for covered drugs based on the plan's actual acquisition cost (the negotiated net price paid by the plan) rather than the drug's wholesale price, starting in 2026. This change directly affects Medicare Part D beneficiaries who pay coinsurance after meeting their deductible but before reaching the out-of-pocket threshold. The bill mandates that plans use the actual cost reported in the Detailed DIR Report, excluding certain drugs covered under specific exceptions. This policy aims to lower out-of-pocket costs for seniors by aligning coinsurance with the price the plan actually pays for medications.
This bill, S 2770 (Share the Savings with Seniors Act), changes Medicare Part D drug coverage for seniors taking specific chronic medications. It requires that for covered chronic care drugs (like blood glucose regulators, anticoagulants, and certain inhalers), beneficiaries pay no more than the drug’s actual negotiated price (net price) for costs below the deductible, and coinsurance above the deductible must be based on that net price. The rules apply to plan years starting January 1, 2027, directly affecting Medicare Part D enrollees using drugs in the defined categories. The bill clarifies that cost-sharing for these drugs cannot exceed the negotiated price, aiming to reduce out-of-pocket costs for seniors on long-term medications.
This bill temporarily allows doctors to prescribe and dispense certain Medicare-covered medications directly to seniors in their offices from 2026 to 2030, under specific conditions. It requires prior in-person visits, limits dispensing to group practices, and mandates billing through the physician’s practice. The bill also directs the GAO to study whether physician-owned pharmacies are becoming common and how such arrangements might affect prescribing. It directly affects seniors receiving Medicare Part D drugs and physician practices participating in these arrangements. The exception expires in 2030, with no changes to Medicare Part D program rules.
This bill changes how Medicare Part D coinsurance is calculated for seniors. Starting in 2026, for drug costs above the deductible but below the out-of-pocket limit, coinsurance will be based on the drug's *net price* (the actual negotiated price after manufacturer discounts) instead of the list price. It directly affects Medicare Part D beneficiaries and prescription drug plans by requiring plans to use the net price when calculating these costs. The net price is defined as the discounted price reported in the Detailed DIR Report, excluding manufacturer discounts. This change aims to reduce out-of-pocket costs for seniors by aligning coinsurance with the lower price paid by the plan.
